M. I. Soykher

M. I. Soykher

Auto-generated profile, based on publicly available information

M. I. Soykher

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2019 in Neuromuscular Diseases
Verified
Journal Article
Open access
OOOlga Orlova
Olga Orlova
MSM. I. Soykher
M. I. Soykher
MSM. G. Soykher
M. G. Soykher
LML. R. Mingazova
L. R. Mingazova
DMD. V. Medovnikova
D. V. Medovnikova
AAA. Yu. Alekseeva
A. Yu. Alekseeva
The article substantiates the need for the use of botulinum therapy in the management of bruxism as a movement disorder. We present the technique of injecting a new Russian botulinum neuroprotein Relatox into the masticatory muscles of patients with bruxism. We have the positive clinical effects of botulinum therapy, a decrease in the level of pain on the visual analogue scale, normalization of muscle activity according to the surface electromyography of masticatory muscles, a decrease in number of nocturnal bruxism according to abrasion on the foil surface on Brux Checker are shown.

2 July 2025 in Russian Journal of Pain
Verified
Journal Article
Closed access
LML.R. Mingazova
L.R. Mingazova
OOOlga Orlova
Olga Orlova
MSM.I. Soykher
M.I. Soykher
AAA.R. Artemenko
A.R. Artemenko
Myofascial orofacial pain (MOP) is caused by damage to the masticatory muscles. It is the leading one in the overall structure of all prosopalgias. Neuropathic signs are found in the clinical picture of the disease, which leads to overdiagnosis of trigeminal neuropathy. The search for mechanism-based therapy that will ensure adequate pain control is an urgent task. To this end, it is necessary to study in more detail the pathogenetic mechanisms of pain in MOP. The purpose of the study. To determine the main mechanisms of the formation of chronic pain in myofascial orofacial pain; to clarify the possibilities of botulinum therapy, taking into account the known facts about the analgesic effect and the effect on neuroplasticity of botulinum toxin type A. Materials and methods. A prospective study was conducted in which 205 patients (123 women, 82 men) with MOP aged 35 to 51 years participated. Clinical neurological studies and neuropathic pain screening were conducted using the DN4 and painDETECT questionnaires. Emotional disorders (depression and anxiety) were studied using the Beck and Spielberger questionnaires. Thirty patients with MOP underwent botulinum therapy of the masticatory muscles using botulinum toxin type A (Relatox) for muscle relaxant and analgesic purposes, as well as studies of the effect of botulinum toxin on the mechanisms of central sensitization. Results. All patients with MOP had aching, pressing, and bursting pains in the parotid-masticatory region. Bimanual palpation of the masticatory muscles revealed myofascial trigger points, the irritation of which caused increased pain. In a clinical study of patients with MOP, spontaneous and evoked sensory phenomena were identified. Spontaneous disorders in the form of numbness, tingling, cold, and burning were reported in 24.3% (n=50) of cases. The induced sensory disorders in the form of cutaneous allodynia were determined on the side of pain localization in the parotid-masticatory region, as well as in another region — on the skin of the upper auricle and temporal region (29.2%, n=60), which corresponds to the innervation zone of the auritotemporal nerve (V3). The phenomena of secondary hyperalgesia (18%, n=37) were detected in the extratrigeminal, namely in the cervical-occipital region on the pain side. When examining the sensitivity to a needle prick in this area, increased pain in the face was determined. An analysis of the data obtained from the DN4 and painDETECT questionnaires in patients with MOP revealed neuropathic descriptors: a feeling of numbness — 35%, tingling — 22%, burning — 19%, chilliness (feeling cold) — 15%, the presence of cutaneous allodynia (pain on a non-painful stimulus) was noted by 23% of patients. As a result of the test study, the patients were divided into two groups: group 1 — with the presence of neuropathic pain according to the DN4 questionnaire (DN4 ≥4 points); group 2 — without neuropathic pain according to the DN4 questionnaire (DN4<4 points). Patients in group 1 were characterized by higher pain intensity on the visual-analog scale (VAS): 6.9±0.98 points versus 5.5±0.82 points (p=0.14). When comparing the results of the assessment of reactive anxiety (RA) and personal anxiety (PA), significantly high values were revealed in patients with neuropathic pain (DN4 ≥4): RA 50.4±1.7 points versus 40.2±2.5 points (p<0.05); PA 50.8±3.5 points versus 31.7±2.1 points (p<0.05). The level of depression in group 1 patients was also significantly higher than in group 2 patients: 25.2±1.8 points versus 15.3±3.1 points (p<0.05). Emotional disorders in the form of high levels of anxiety and depression determine the special behavior of the patient, lead to a significant limitation of coping strategies. The dynamics of clinical manifestations and testing in 30 patients who received local injections of botulinum toxin type A (Relatox) into the masticatory muscles was as follows. 1 month after the procedure, there was a significant decrease in VAS pain intensity in both groups of patients (6.2 points at the beginning versus 4.8 points after 1 month in the 1st group, p<0.01). Sensory phenomena also underwent positive changes. The dynamics of the representation of spontaneous sensory disorders showed the following: 33% at the start of therapy versus 9.5% after 1 month (p<0.01); the representation of induced sensory disorders: 23.8% at the beginning versus 4.7% after 1 month (p<0.01); secondary hyperalgesia: 12.5% at the start versus 3.5% after 1 month (p<0.01). The data obtained from anxiety and depression questionnaires showed good dynamics: RA/PA 49.6±1.2/47.3±1.8 points versus 25.4±2.1/23.8±2.3 points after 1 month (p<0.01); depression 23.9±1.3 points versus 18.2±2.2 points after 1 month (p<0.01). The results of the dynamics of psychological questionnaires correlate with good dynamics on the pain catastrophization scale (18.2±2.9 points at the start of therapy versus 14.4±3.3 points after 1 month, p<0.01). Conclusion. The data obtained showed the involvement of two mechanisms in the pathogenesis of chronic myofascial orofacial pain: nociceptive and dysfunctional. In 35% of cases, central sensitization plays a leading role and determines the presence of dysfunctional pain in the structure of chronic myofascial pain. In this regard, the protocol for the treatment of chronic myofascial orofacial pain should include an effect on all pathogenesis factors. Local injections of botulinum toxin type A are a universal method of influencing the mechanisms of peripheral and central sensitization due to the selective muscle relaxant, analgesic effect. The effect of botulinum therapy on sensory symptoms may be related to the decompression of neurovascular structures, which presumably occurs during muscle relaxation of the masticatory and temporal...

15 October 2023 in Medical alphabet
Verified
Journal Article
Open access
PDF file
EAE. N. Anisimova
E. N. Anisimova
NAN. Y. Anisimova
N. Y. Anisimova
MSM. I. Soykher
M. I. Soykher
OKO. V. Khodnenko
O. V. Khodnenko
EYE. A. Yerilin
E. A. Yerilin
IKI. A. Kravchenko
I. A. Kravchenko
Relevance. Effective pain relief is required for high-quality outpatient dental treatment in children. Рeriodontal local anesthetic methods are easier to implement and safer for young patients. Purpose. To conduct a comparative analysis of the use of various local anesthetics when using a modified periodontal method in the treatment of caries and pulpitis of permanent teeth in children 7–12 years old at an outpatient dental appointment. Materials and methods. The study involved 108 children of the 7–12 years old age group, who need treatment for caries and pulpitis of permanent molars. Local anesthetic was administrated 4% solution of articaine without a vasoconstrictor, with epinephrine at concentrations of 1:200,000, 1:400,000, 2% solution of articaine without a vasoconstrictor and with epinephrine 1:200,000. To determine the effectiveness of the treatment a developed analog-visual scale was used. Results. The high efficiency and safety of the use of modified periodontal anesthesia using 2 and 4% solutions of articaine with epinephrine in the treatment of permanent molars in children aged 7–12 years was determined.

3 January 2026 in Medical alphabet
Verified
Journal Article
Closed access
MSM. I. Soykher
M. I. Soykher
MSM. G. Soykher
M. G. Soykher
LML. R. Mingazova
L. R. Mingazova
DTD. A. Trunin
D. A. Trunin
VGV. V. Govenko
V. V. Govenko
The polyetiology and diversity of manifestations of bruxism, which is accompanied by increased muscle activity, cause certain difficulties in choosing treatment methods. When analyzing recent systematic reviews of the literature on cases of drug-induced bruxism, the most common side effect in the form of jaw clenching occurred when taking selective serotonin reuptake inhibitors, especially fluoxetine, venlafaxine, and sertraline. The lack of a unified methodological approach to the diagnosis and treatment of patients with bruxism, including drug-induced bruxism, makes it difficult to plan treatment measures and prevent the development of this pathological condition. Therefore, therapy in such cases is symptomatic and aimed at preventing damage to the dental and maxillofacial system and orthopedic structures.

2 March 2022 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
LML. R. Mingazova
L. R. Mingazova
OOOlga Orlova
Olga Orlova
MSM. I. Soikher
M. I. Soikher
Neuropathic orofacial pain caused by trauma to the distal branches of the trigeminal nerve is most often an iatrogenic complication in the practice of dentists, maxillofacial surgeons, ENT surgeons, cosmetologists and plastic surgeons. The pain is often high-intensity, persistent, and difficult to treat with pain medications. Early signs of spontaneous pain aggravate the course of the disease. There is evidence of the use of N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of neuropathic pain in the practice of oncologists and diabetologists. The present study was designed to test the efficacy of administration of the NMDA receptor antagonist amantadine (PK-Merz) in the treatment of neuropathic orofacial pain in patients with posttraumatic trigeminal neuropathy (PTN). Our task was to study the effect of amantadine (PK-Merz) on spontaneous burning and evoked types of pain.Objective.To present a treatment protocol using amantadine (PK-Merz) and evaluate the effect of a three-time infusion of the drug on the clinical manifestations of pain in patients with post-traumatic trigeminal neuropathy.Materials and methods.30 patients were examined (22 women, 8 men). The average age is 42.6 years. Patients are experiencing amantadine (PK-Merz, Merz + Co., Germany) – 200 mg (500 ml) intravenously, drip, for 2 hours with a frequency of 1 time per week. A total of three infusions were performed. Spontaneous and evoked pain was measured within 48 hours before treatment, during treatment (after 1 hour), immediately after infusion (after 2 hours), as well as after 7, 14 and 21 days from the start of therapy. The effectiveness of therapy was studied according to the highest criteria: VAS, questionnaires for neuropathic pain DN 4 and Pain DETECT. Spontaneous and induced pain were considered separately. To assess the immediate effects of treatment, spontaneous pain was measured using a visual analog scale (VAS) before, after 1 hour, and at the end of each treatment (after 2 hours), as well as at visits on days 7th, 14th, and 21st. A series of mechanical and thermal stimuli was applied to each patient before, after 1 hour, and at the end of each treatment session to study the pain evoked. Pain caused by these stimuli was also measured using VAS.Results.The patients were divided into two groups, which were formed according to the duration of the disease. Group 1 (n = 12) included patients in the acute period – the time after nerve injury ranged from 5 to 30 days. In group 2, patients were in subacute and chronic periods (time after injury ranged from 30 days to 1.5 years). The mean score of spontaneous pain according to VAS in patients of group 2 was significantly higher than in patients of group 1 (6.1 ± 2.1 vs 4.2 ± 1.6; p = 0.0001). A mean pain reduction of 71 % was reported at the end of amantadine infusion (after 2 hours) in patients in the acute period (Group 1) compared with 29 % in patients in Group 2. The difference in pain reduction between the two patient groups was statistically significant (p = 0.009). Further dynamics of pain also showed the best analgesic result in patients of group 1 – after the completion of treatment with amantadine (PK-Merz), in patients of group 1, a significant decrease in the average score of spontaneous burning pain according to VAS was demonstrated from 4.2 ± 1.6 points to 1.2 ± 1.1 points (p = 0.006; 71 ± 10 % reduction). After treatment of patients in group 2, only a slight and insignificant decrease in VAS was found from 6.1 ± 2.1 to 5.0 ± 1.7 (p = 0.400; 18.0 ± 8.5 %). Symptoms of induced pain were determined mainly among patients of the 2nd group – allodynia (n = 12), hyperalgesia to a needle prick (n = 10), thermal (cold) hyperalgesia (n = 10), "inflated" pain in response to repeated injections (n = 10). A mean decrease in allodynia of 52 % ± 8 % was found at the end of the course of treatment (3.8 ± 1.1 points at the beginning and 1.9 ± 1.1 points at the end; p = 0.006). Indicators of cold hyperalgesia (4.4 ± 1.4 points at the beginning, 2.7 ± 1.4 points at the end; p = 0.004) and ‘inflated’ pain (2.9 ± 1.1 points at the beginning, 1.5 ± 1.2 at the end; p = 0.004) before treatment and at the end of therapy (after 21 days) also differed significantly.Conclusions.We concluded that amantadine (PK-Merz) infusion is a safe and effective treatment for neuropathic pain in the acute period of KITN, and also has a positive effect on the manifestations of induced pain in patients with chronic orofacial pain. Further trials of long-term oral or parenteral treatment with amantadine should be conducted.

3 January 2026 in Medical alphabet
Verified
Journal Article
Closed access
EFE. V. Filimonova
E. V. Filimonova
EBE. S. Bukharina
E. S. Bukharina
MSM. I. Soуkher
M. I. Soуkher
DSD. I. Shevlyakov
D. I. Shevlyakov
EDE. A. Daskal
E. A. Daskal
The high prevalence of dental caries in primary teeth among young patients and children with comorbidities remains a critical issue in pediatric dentistry and requires the exploration of effective solutions. The purpose of the study is to develop an algorithm for providing dental care to children under general anesthesia. Materials and methods. A total of 398 medical records of children treated under GA at the Moscow Regional Dental Clinic were analyzed. The dental status of patients, stages of treatment preparation, and outcomes of dental treatment under GA were evaluated for healthy children (group 1) and children with comorbidities (group 2). Results. The duration of anesthesia in both groups was contingent upon the extent of the treatment and revealed no statistically significant differences between the groups (120.81±36.05 mi-nutes and 124.57±43.00 minutes, p>0.05). The mean number of teeth treated for pulpitis and the number of crowns placed were significantly greater in Group 1 (p<0.05). Moreover, there was a statistically significant increase in the number of tooth extractions among children in Group 2 (2.54±2.90 and 3.57±3.77, p<0.05). Conclusions. For children with severe comorbid conditions, comprehensive dental treatment and an expanded indication for tooth extraction are essential to reduce the risk of repeated interventions. The limitations of therapeutic procedures underscore the need for an individualized approach to early prevention. When planning treatment involving general anesthesia, it is crucial to clearly define the indications and contraindications, ensure the possibility of medical check-ups at the patient’s residence, maintain effective communication with parents, and collaborate with colleagues at every stage of treatment. These factors are key to enhancing the organization of dental care for children undergoing general anesthesia.